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Objectives: Direct observation of health care processes through time and motion 
(T&M) studies is increasingly warranted to provide evidence of medication or device 
efficiency. This methodology can be leveraged to collect comprehensive data on 
patient characteristics, and health and care process outcomes. A hybrid T&M plus 
patient survey & chart review study design is described through case study presen-
tation and summary of lessons learned. MethOds: A prospective, observational, 
hybrid T&M study of subcutaneous immunotherapy (SCIT) administration was 
conducted at 12 sites (US and Canada). Process time and supplies consumed were 
collected through observation of SCIT visits and serum preparation. Chart reviews 
provided medical history and resource utilization; trained observers collected soci-
odemographics, loss of productivity, medication use, and travel time by survey. 
Site staff estimated time for administrative tasks related to SCIT. Results: Key 
considerations for study design and CRF development: comprehensive care process 
mapping and minimization of patient/site burden, handling treatment process vari-
ability, and maximizing generalizability of results. Site and observer recruitment, 
minimizing impact on treatment delivery, and ensuring uniformity of data col-
lection methods across sites were main operational considerations. An extensive 
study planning process along with nurse observers utilized for data collection led 
to successful completion of the study at six sites/country (primary care, allergists, 
otolaryngologists), with 670 patients. The final robust dataset consisted of observed 
treatment delivery steps and timings for staff and patients at SCIT visits (2-8 and 
4-32 min respectively, plus 2-33 min post-injection wait), patient-reported travel 
times (34-50 minutes), and detailed information regarding number/type of aller-
gens per patient through chart review. cOnclusiOns: T&M methodology allows 
for prospective data collection of observed processes, providing data on process 
efficiency and cost drivers that are often otherwise unavailable. This approach can 
be successfully combined with medical chart review and patient and site question-
naires to optimize evidence generation.
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Objectives: To understand how registries are being utilized in current post-market-
ing research. MethOds: A targeted search was conducted in MEDLINE to identify 
all original research published in 2013 reporting results from registries. The search 
was restricted to English language publications. Abstracts of relevant citations were 
reviewed to obtain the country of study, therapeutic area and registry design. A 
supplementary search of registries listed on clinicaltrials.govwas conducted to esti-
mate the number of registries currently ongoing. Results: The search returned 
136 citations, containing 128 citations reporting results from 116 unique registries. 
Amongst the 116 registries, n= 43 (37.1%) were conducted in Europe, n= 40 (34.5%) in 
the United States, n= 25 (19.8%) in Asia-Pacific and n= 5 (4.3%) multi-nationally. Most 
registries were studies in cardiology (n= 76 [65.5%]), and n= 9 (7.8%) unique registries 
were devoted to the study of pediatric patient populations. 21.6% of the registries 
were designed to investigate the safety of a medical device or pharmaceutical agent, 
and another n= 34 (29.3%) aimed to evaluate clinical outcomes of surgical interven-
tions. According to clinicaltrials.gov, there are 747 registry studies that are currently 
in active recruiting, or planning status. At the time of this review, 410 registries are 
active in North America and 247 in Europe. cOnclusiOns: The purpose of the 
present review was not to perform an exhaustive summary of all registries but to 
gain a snapshot of what has been published in a given, recent year. Results of this 
review confirm that different registry designs are being used in real-world data col-
lection to meet specific research objectives, be it safety monitoring, understanding 
disease natural history or long-term clinical outcome evaluation. Further analysis 
into the study characteristics will be presented to guide stakeholders in choosing 
appropriate registry designs.
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Objectives: Increasingly, value demonstration evidence requirements cannot 
be addressed with a single data source and/or methodology. The objective of this 
research is to present, using case studies to illustrate, a strategic and step-wise 
approach for the development of optimal study designs to address research ques-
tions which warrant multiple data sources including primary or secondary sources 
of real-world data. MethOds: Steps followed in the conceptualization of designs 
that integrate multiple data sources include: the identification and prioritization 
of research questions, delineation of evidence gaps and potential data sources, 
assessment of data availability by source and feasibility of data integration, study 
synopsis development, data protection and legal reviews, and study protocol 
development. Results: In the first case example, the purpose of the study was 
to understand reasons why patients discontinue therapy for a rare disease. Due to 
the orphan drug status, multiple data sources were needed to identify and recruit 
subjects to participate in the study. A second case study combined the use of a 
patient support program database to identify potential subjects, drug dispensing 
data from a specialty pharmacy to assess medication adherence, and a longitudinal 
patient survey assessing disease activity and patient satisfaction. Finally, two stud-
ies were designed (1 observational, 1 interventional) which utilize pharmacy claims 
data to identify potential subjects and evaluate medication adherence during the 
study period. This data is linked with longitudinal patient surveys evaluating top-
ics including treatment experience, reasons for non-adherence, and experience of 
adverse events. cOnclusiOns: These case studies demonstrate a novel approach 
to study design from within a single research network, whereby data from multiple 
identified with at least 1 ICD-9 code specifying narcolepsy (NDX), each randomly 
matched to 5 controls (no NDX; n= 46,559). A sequential validation process com-
pared claims-measurable outcomes (health care utilization, 7 known narcolepsy-
associated comorbidities) in the 1 NDX population (n= 4,587) against groups having 
2-4 NDX (n= 2,894) and 5+ NDX (n= 1,831), comparing groups to each other and to 
their matched controls. Additional comparisons were made to a reference group 
with the least ambiguous symptom (cataplexy) and an NDX persisting subsequent to 
in-period diagnostic testing (n= 465). Results: 1-way ANOVA showed consistently 
higher utilization among narcolepsy patients compared to controls [all P< 0.001] 
and equivalent utilization between narcolepsy patients, irrespective of the number 
of reported NDX [all P> 0.05], except patients with 1 NDX vs. 5+ NDX (P = 0.047). 
Similarly, chi-square analysis showed high coherence in comorbidities among NDX 
groups and significant differences vs. controls. In sum, patients with a single NDX 
were highly similar to patients with more narcolepsy diagnosis codes and consist-
ently unlike control patients without narcolepsy. Statistical differences observed 
between single NDX patients and the cataplexy subgroup with in-period testing 
will be addressed. cOnclusiOns: The sequential validation process supported 
inclusion of subjects captured by a single diagnosis code in a burden of illness study. 
This approach may prove useful in developing inclusion criteria for claims-based 
studies of other rare or chronic diseases.
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Objectives: Both the FDA and the EMA accept Progression-free Survival (PFS) and 
Disease-free Survival (DFS) as appropriate surrogate outcomes for Overall Survival 
(OS) in clinical trials, but does using PFS or DFS decrease the chances of a positive 
recommendation from Health Technology Assessment (HTA) agencies? MethOds: 
HTA assessments from 10 agencies between 2005 and 2013 for 6 solid-state oncology 
conditions were analyzed. Reviews were grouped by primary outcome as follows: OS, 
PFS, co-primary outcomes, DFS and other. HTA recommendations were categorized 
as positive or negative. Results: A total of 245 reviews were analyzed. Reviews 
that did not report a primary outcome were excluded (17%). The use of primary 
outcome was highly dependent on the cancer. OS was overwhelmingly used in 
melanoma and small-cell lung cancer, while PFS was used in ovarian cancer. Due 
to the lack of variety in the primary outcome used in these cancers, rates of posi-
tive recommendations associated with the choice of primary outcome could not 
be calculated. Colorectal cancer (CC) used PFS, OS and DFS at similar rates (25%, 
26% and 22% respectively; n= 68); Non-small cell lung cancer (NSCLC) used OS and 
PFS at similar rates (44% and 36% respectively; n= 61). The majority of prostate 
cancer (PC) reviews used OS (66%), but 32% used other outcomes (mostly related to 
measuring testosterone levels; n= 38). There was no statistical difference between 
the use of outcomes and the rate of positive recommendation in CC, NSCLC or 
PC. cOnclusiOns: The choice in primary outcome was dependent on the oncology 
condition. The relationship between choice in primary outcome and reimbursement 
recommendation was not significant for oncology conditions that used a variety 
of outcomes. Further research and multivariate analysis is needed to determine if 
the choice of a surrogate outcome in oncology HTA reviews decreases the chances 
of a positive approval.
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Objectives: In the absence of randomized controlled trials (RCTs) and to verify 
RCT evidence, health technology assessment (HTA) agencies commonly rely on non-
RCTs to provide evidence of the effectiveness of health care interventions. This type 
of study design can introduce considerable bias into a systematic review and a num-
ber of methodologies exist to evaluate the risk of bias in such studies. We undertook 
a series of reviews to identify which tools are commonly used in the literature and 
in an HTA setting for critical appraisal of non-RCTs. MethOds: Firstly, a targeted 
search of systematic reviews including non-RCTs was conducted in MEDLINE and 
EMBASE (OVID SP). Studies identified were reviewed to determine which appraisal 
tool, if any, was used. Secondly, recommendations for the critical appraisal of non-
RCTs by expert review groups (Cochrane, Centre for Reviews and Disseminations 
(CRD)) and HTA bodies (including NICE, SMC, NCPE, AWMSG, IQWiG, PBAC, AMCP 
and CADTH) were reviewed. Criteria covered by each tool were recorded. Results: 
446 studies were identified by the targeted search and were screened. We identified 
a large number of critical appraisal tools. Commonly used tools included Downs & 
Black, Chalmers, the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither the 
Cochrane Collaboration nor CRD recommend a particular risk of bias instrument. 
Only one HTA body, CADTH, recommend use of a specific critical appraisal tool; 
SIGN 50 (for cohort or case-control studies). The tools identified examine a vari-
ety of criteria including reporting, external validity, bias, confounding, power and 
temporal parallelism. cOnclusiOns: There is a lack of consensus on a preferred 
instrument that allows for the assessment of all types of non-RCT evidence. As a 
result, critical appraisal of non-RCTs is often omitted from HTA submissions. There 
is thus a need for cross communication between groups to reach a consensus and 
develop a suitable tool.
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develop while clarity on methods to evaluate the cognitive impact of this technol-
ogy have lagged. The steps we present provide a standardized system for ensuring 
that ePROs measure what is intended and the risk to research data is minimized.
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Objectives: Although missing and incomplete responses in ePROs can be mini-
mized through risk assessment and mitigation plans, missing data can have varying 
implications on clinical trials. This conceptual paper assesses the impact of missing 
ePRO data to the trial, taking into account the phase of the trial and intended use 
of the data. MethOds: Common uses for data gathered via ePRO instruments and 
diaries are reviewed. An assessment of the impact of different levels of missing 
data and associated risks with analyzing data is also performed. Results: Data 
gathered via ePRO are frequently used to support primary/secondary trial endpoints. 
They are also commonly used for exploratory purposes, allowing sponsors to gather 
preliminary information to guide the planning of future trials. Types of data col-
lected may include study medication usage for study drug reconciliation reasons, 
symptom presence or severity to determine eligibility for trial participation, and 
responses over time to indicate improvement or worsening of the symptom/disease. 
Each data use is assessed for risks to the analyzability of the data associated with 
different levels of missing data. For example, in projects with ePRO responses used 
to support primary/secondary endpoints overall project risk is low when compliance 
rates are high (e.g. 90-100%). As compliance rates drop to < 80%, bias introduced in 
the results increases, quality of the data decreases, and risks that the data may 
not be able to be used in the analysis rises. Impacts could include a need to recruit 
additional patients or that the trial may need to be re-run. cOnclusiOns: Impacts 
of missing data on clinical trial analysis vary depending on the intended use of the 
data. It is important to understand the impact of missing data to the project so that 
an appropriate plan can be decided upon and included in the protocol.
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Objectives: Retrospective medical chart reviews are an increasingly valuable 
source of data for clinical, treatment patterns, and outcomes research, particularly 
in emerging markets where availability of databases for secondary analysis is lim-
ited. This abstract aims to describe methodological and operational considerations 
that sponsors and researchers should be aware of prior to and during the undertak-
ing of chart review studies in these markets. MethOds: Key considerations for 
executing chart review studies in hospitals and major medical centers from study 
conception through the completion and quality review of data collection were iden-
tified and summarized. Results: After identification of research objectives and 
target countries/markets for research, thoughtful consideration of site selection 
(single or multi-site/country, local investigator interest and availability), data avail-
ability (nature, comprehensiveness, and quality of existing medical records), and 
patient selection (sampling design, specificity of inclusion/exclusion criteria) form 
the basis for implementing a successful chart review. Study design steps may be 
taken to optimize performance, for example: careful consideration of how inclusion/ 
exclusion criteria will impact patient recruitment given the rarity of the study condi-
tion (data on this may be limited); assessing feasibility of data collection instrument 
completion via piloting and prior local experience; standardization of terms and 
definitions to ensure cross-site comparability. Additional operational considerations 
include meeting varied requirements for obtaining national/state and local ethics 
approval in multi-country studies, use of electronic data capture given variation in 
information technology infrastructure across study sites, and impact of workday/
cultural traditions on recruitment/ timelines. cOnclusiOns: To maximize the 
opportunity for successful medical chart review studies in emerging markets, review 
and assessment of operational feasibilities in the target research areas, appropriate 
tailoring of study objectives, engagement of local investigators and site staff, and 
continuous oversight of data collection and quality control processes are essential.
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It is often the case that cost-effectiveness models need to consider the sequence 
of treatments in a treatment algorithm. Since traditional state transition Markov 
models have an inherent memoryless property, time dependency in time to event 
analysis cannot be incorporated in this modelling framework. This has been used 
as a rationale for moving to individual level simulation models to handle treatment 
sequences. However, individual simulation models increase the computational bur-
den of a model, particularly when it comes to undertaking real-time probabilistic 
sensitivity analysis to characterize uncertainty. Therefore, adifferent approach to 
modeling treatment sequencing should be examined. In this paper, we discuss a 
novel approach to analyzing sequencing models that allow time dependency in the 
time to event analysis within a cohort model framework,thus avoiding the disad-
vantages of resorting to individual simulation. Typically parametric survival models 
can be used to characterize time to event. This may be time to overall survival or 
time to progression in cancer modelling, or time to treatment failure / treatment 
switching in oncology. We illustrate the approach using parametricWeibull models, 
although in principle any parametric survival model could be used. We show how 
sources may be integrated in order implement prospective observational research 
studies that answer complex research questions.
ReseaRch on Methods – conceptual Papers
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Objectives: Health economic models are widely used for drug evaluation during 
the post-approval and reimbursement process. However, similar models can also 
be used to inform objectives, decisions and designs earlier in the drug develop-
ment process with the idea to optimize the potential future value to payers. This 
project assesses how an economic heart failure (HF) model can facilitate the deci-
sion making process during the early stages of drug development. MethOds: A 
discrete event simulation is developed to track the events associated with disease 
progression of HF patients over 5 years. Patients are initially categorized into one 
of three health states based on their HF status: in-hospital, 30 days post-discharge 
and > 30 days post-discharge. To capture movement in the model, the time to hos-
pital discharge, re-hospitalization and death are generated based on each patient’s 
current health state and the event rates taken from available literature. The model 
is used to identify baseline levels of risk, a range of potential prices or the required 
drug efficacy that the drug candidate needs to meet in order to be cost-effective 
compared to standard care. Results: By way of illustration, we considered a patient 
with baseline mortality risk of 0.1% and a 0.2% readmission rate per day. If treatment 
costing $1 /day is provided to patients outside of hospital, a mortality reduction of at 
least 12% is needed to meet a $25,000/QALY threshold. For a higher risk population, 
the treatment can remain cost-effective at either a higher price or lower clinical 
efficacy. cOnclusiOns: This study demonstrates that health economic models 
are useful to determine the acceptable ranges of baseline risk, efficacy, and price to 
assess the potential value of future drug candidates.
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Objectives: To explore the appropriate use of surrogates within an economic 
modeling framework, compared to the statistical approaches of validating sur-
rogates. MethOds: We reviewed the statistical literature on validating surrogate 
endpoints. Published statistical approached to validating surrogate endpoints 
include those described by Prentice and Buyse. We explore the use of these sta-
tistical approaches to validation in the context of health economic models where 
surrogates are used (a) predict final outcomes, and (b) as endpoints for stopping 
rules and patient access schemes. Results: Given regulatory trials powered on 
surrogate endpoints, economic modeling often requires the use of surrogate end-
points to estimate the impact of treatment on final health outcomes of interest to 
reimbursement agencies. This requirement occurs even when there is no statisti-
cal validation of the surrogacy relationship, or when the surrogate fails a formal 
statistical validation. As a consequence we argue that the appropriate focus for 
economic modeling is on the appropriate propagation of uncertainty in the esti-
mates of the effect of the surrogate on final health outcome and the avoidance of 
bias due to multiple testing rather than the formal testing of validity. This includes 
the use of stopping rules that are designed to improve cost-effectiveness estimates 
for patient access. cOnclusiOns: The approach to surrogacy in reimbursement 
is necessarily different to that in a regulatory environment. We outline a general 
estimation approach based on appropriately characterizing uncertainty in the sur-
rogacy relationship rather than the formal statistical testing of surrogate validity 
as the appropriate focus of reimbursement models.
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AiMs: Use of electronically administered outcome measures is increasing in clinical 
trial data collection. The 2009 ISPOR ePRO Task Force Report recommends cogni-
tive assessment as sufficient evidence of equivalence when only minor changes 
have been made to the measure. No consensus exists, however, for how cognitive 
assessment results should be evaluated to determine if equivalence has been estab-
lished. MethOds: Existing literature around equivalence assessment for PROs was 
combined with firsthand experience in conducting over 500 cognitive interviews 
aimed at assessing paper and electronic equivalence of 55 different PRO instru-
ments. Using these two resources, we developed suggested criteria to cognitively 
assess equivalence between the two modes, and present a practical process for 
meeting these criteria. Results: The criteria for determining equivalence between 
paper and ePRO formats should focus primarily on whether or not the ePRO is likely 
to produce data substantially different if administered via one method versus the 
other. To determine whether such a risk to ePRO data exists, we propose a three-
step process for interpreting cognitive interview responses. 1) Determine whether a 
patient perceives a cognitive difference between paper PRO and ePRO, and whether 
that difference represents a variation in the understanding of the item or simply a 
recognition of different appearance; 2) Determine whether any difference in patient 
understanding has a meaningful impact on their response to the item, and 3) deter-
mine whether or not that difference presents a significant risk to the data that 
justifies modification of the ePRO. cOnclusiOns: In the years since the ISPOR ePRO 
Task Force issued their recommendations, data capture technology has continued to 
